Interstitial lung disease in systemic sclerosis (systemic scleroderma)

In systemic sclerosis (SSc), interstitial lung disease (ILD) is common (>80%) and worsens the prognosis of disease, but severe progressive damage develops only in 8–10% cases. Interstitial changes lungs occur early (within first 3–5 years disease). The histological manifestations are similar to those idiopathic ILD. main tool for screening diagnosing ILD associated with SSc high-resolution computed tomography lungs, resulting data influence choice therapy. most patients a relatively intact stable forced vital capacity recorded long time, diffusion decreases steadily. Pulmonary functional tests have prognostic value. optimal therapy lesions based on general activity (the severity inflammation fibrosis) its severity, rate progression leading pathology – pneumonia (IP) particular. or IP, treatment mycophenolate mofetil (MMF), cyclophosphamide, nintedanib, nintedanib combination MMF if appropriate, should be considered. If this ineffective, rituximab may used.